Diagnostic Microbiology & Infectious Disease
Volume 66, Issue 3 , Pages 308-313 , March 2010

Susceptibility to tigecycline of isolates from samples collected in hospitalized patients with secondary peritonitis undergoing surgery

  • Fe Tubau

      Affiliations

    • Microbiology Department, Hospital Universitari de Bellvitge, IDIBELL, University of Barcelona, Feixa Llarga, s/n, 08907 Hospitalet de Llobregat, Barcelona, Spain and CIBER for Respiratory Diseases
    • ,
  • Josefina Liñares

      Affiliations

    • Microbiology Department, Hospital Universitari de Bellvitge, IDIBELL, University of Barcelona, Feixa Llarga, s/n, 08907 Hospitalet de Llobregat, Barcelona, Spain and CIBER for Respiratory Diseases
    • ,
  • Maria-Dolores Rodríguez

      Affiliations

    • Microbiology Department, Hospital Arquitecto Marcide-Novoa Santos, Estrada de San Pedro de Leixa s/n, 15405 Ferrol, A Coruña, Spain
    • ,
  • Emilia Cercenado

      Affiliations

    • Microbiology Department, Hospital General Universitario Gregorio Marañón, Dr. Esquerdo 46, 28007 Madrid, Spain
    • ,
  • Maria-Jose Aldea

      Affiliations

    • Microbiology Department, Hospital Royo Villanova, Avda. San Gregorio 30, 50015 Zaragoza, Spain
    • ,
  • Fernando González-Romo

      Affiliations

    • Microbiology Department, Hospital Universitario San Carlos, Martin Lagos s/n, 28040 Madrid, Spain
    • ,
  • Luis Torroba

      Affiliations

    • Microbiology Department, Hospital Virgen del Camino, Irunlarrea 4, 31008 Pamplona, Spain
    • ,
  • Pilar Berdonces

      Affiliations

    • Microbiology Department, Hospital de Galdakao, Barrio Labeaga s/n, 48960 Galdakao, Vizcaya, Spain
    • ,
  • Joaquin Plazas

      Affiliations

    • Microbiology Department, Hospital General Universitario de Alicante, Maestro Alonso 109, 03010 Alicante, Spain
    • ,
  • Lorenzo Aguilar

      Affiliations

    • Microbiology Department, School of Medicine, Universidad Complutense, Avda. Complutense s/n, 28040 Madrid, Spain
    • Corresponding Author InformationCorresponding author. Tel.: +34-91-3941505; fax: +34-91-3941511.
    • ,
  • Alberto Delgado

      Affiliations

    • Microbiology Department, Hospital Universitario Fundación de Alcorcón, Budapest 1, 28922 Alcorcón, Madrid, Spain
    • ,
  • Nuria García-Escribano

      Affiliations

    • Medical Department, Wyeth Farma S.A., Ctra. N-I, km. 23 Desvío Algete Km.1, San Sebastián de los Reyes, Madrid, Spain
    • NG-E is an employee of Wyeth Farma, Madrid, Spain.
    • ,
  • on behalf of the study group

Received 8 July 2009 ,Accepted 30 October 2009.

References 

  1. Babinchak T, Ellis-Grosse E, Dartois N, Rose GM, Loh E Tigecycline 301 Study Group Tigecycline 306 Study Group. The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data. Clin. Infect. Dis. 2005;41(Suppl 5):S354–S367
  2. Bolmström A, Karlsson A, Engelhardt A, Ho P, Petersen PJ, Bradford PA, et al. Validation and reproducibility assessment of tigecycline MIC determinations by Etest. J. Clin. Microbiol. 2007;45:2474–2479
  3. British Society for Antimicrobial Chemotherapy . http://www.bsac.org.uk/susceptibility_testing/breakpoints.cfm(last access 7 July 2009)
  4. Camarena JJ, Gonzalez R, Zaragoza R, Navarro JC, Sancho S, Nogueira JM. Actividad in vitro de tigeciclina frente Acinetobacter baumannii: variaciones de CMIs por E-test dependientes del tipo de medio Mueller–Hinton II utilizado en rutina. Abstracts of the 12th Reunión de la Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica (SEIMC), Abstract 025, Enferm. Infect. Microbiol. Clin. 2007;25(Espec Congr):58
  5. Casal M, Rodríguez F, Johnson B, Garduno E, Tubau F, de Lejarazu RO, et al. Influence of testing methodology on the tigecycline activity profile against presumably tigecycline-non-susceptible Acinetobacter spp. J. Antimicrob. Chemother. 2009;64:69–72
  6. Clinical and Laboratory Standards Institute (CLSI) . Methods for antimicrobial susceptibility testing of anaerobic bacteria; approved standard—seventh edition, M11-A7. Wayne, PA: CLSI; 2007;
  7. Clinical and Laboratory Standards Institute (CLSI) . Performance standards for antimicrobial susceptibility testing: 70th informational supplement (M100-S17). Wayne, PA: CLSI; 2007;
  8. European Committee on Antimicrobial Susceptibility Testing . http://www.srga.org/eucastwt/MICTAB/MICtetracyclines.htm(last access 7 July 2009)
  9. Fernández-Mazarrasa C, Mazarrasa O, Calvo J, del Arco A, Martínez-Martínez L. High concentrations of manganese in Mueller–Hinton agar increase MICs of tigecycline determined by Etest. J. Clin. Microbiol. 2009;47:827–829
  10. Food and Drug Administration . Tygacil label information. http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021821s013s017s018lbl.pdf(last access 7 July 2009)
  11. Giménez MJ, Barberán J, Aguilar L. Therapeutic efficacy, animal models and experimental pharmacodynamics: what do we know about tigecycline? [Article in Spanish]. Rev. Esp. Quimioterap. 2007;20:387–394
  12. Meagher AK, Ambrose PG, Grasela TH, Ellis-Grosse EJ. Pharmacokinetic/pharmacodynamic profile for tigecycline—a new glycylcycline antimicrobial agent. Diagn. Microbiol. Infect. Dis. 2005;52:165–171
  13. Montravers P, Lepape A, Dubreuil L, Gauzit R, Pean Y, Benchimol D, et al. Clinical and microbiological profiles of community-acquired and nosocomial intra-abdominal infections: results of the French prospective, observational EBIIA study. J. Antimicrob. Chemother. 2009;63:785–794
  14. Muralidharan G, Micalizzi M, Speth J, Raible D, Troy S. Pharmacokinetics of tigecycline after single and multiple doses in healthy subjects. Antimicrob. Agents Chemother. 2005;49:220–229
  15. Oliva ME, Rekha A, Yellin A, Pasternak J, Campos M, Rose GM, et al. A multicenter trial of the efficacy and safety of tigecycline versus imipenem/cilastatin in patients with complicated intra-abdominal infections [Study ID Numbers: 3074A1-301-WW; ClinicalTrials.gov Identifier: NCT00081744]. BMC Infect. Dis. 2005;5:88
  16. Onderdonk AB, Tzianabos A. Assessment of tigecycline (GAR-936) efficacy in a rat model for intra-abdominal sepsis. Abstracts of 3rd World Congress on Anaerobic Bacteria and Infections. Anaerobe. 2003;9:247–276
  17. Passarell JA, Meagher AK, Liolios K, Cirincione BB, Van Wart SA, Babinchak T, et al. Exposure-response analyses of tigecycline efficacy in patients with complicated intraabdominal infections. Antimicrob. Agents Chemother. 2008;52:204–210
  18. Pillar CM, Draghi DC, Dowzicky MJ, Sahm DF. In vitro activity of tigecycline against gram-positive and gram-negative pathogens as evaluated by broth microdilution and Etest. J. Clin. Microbiol. 2008;46:2862–2867
  19. Rodvold KA, Gotfried MH, Cwik M, Korth-Bradley JM, Dukart G, Ellis-Grosse EJ. Serum, tissue and body fluid concentrations of tigecycline after a single 100 mg dose. J. Antimicrob. Chemother. 2006;58:1221–1229
  20. Van Ogtrop ML, Andes D, Stamstad TJ, Conklin B, Weiss WJ, Craig WA, et al. In vivo pharmacodynamic activities of two glycylcyclines (GAR-936 and WAY 152,288) against various gram-positive and gram-negative bacteria. Antimicrob. Agents Chemother. 2000;44:943–949

☆ This study was supported in part by an unrestricted grant from Wyeth Farma, Madrid, Spain.

PII: S0732-8893(09)00443-X

doi: 10.1016/j.diagmicrobio.2009.10.018

Diagnostic Microbiology & Infectious Disease
Volume 66, Issue 3 , Pages 308-313 , March 2010

Article Tools